Escape immune destruction Tion should be viewed as an emergent property of cancer. Highly immunogenic cancer cyards can be eliminated in immunocompetent immunoediting after. Weakly immunogenic variants k Can cro His and produce solid tumors. Regulatory T cells were found to maintain the immune tolerance to both the prevention of autoimmune diseases, and reduce the anti-tumor AZD6482 immune response may be involved. Modulation of immune responses in patients with cancer is the result of a balanced activity t of Treg cells and T eff ector. Cancer patients, an increase in the number of Tregs was found in tumor tissue and blood: It was found that Tregs to suppress the response of T-cells and natural killer-cell proliferation and function, st Ren both acquired immunity t and innate. Upregulation of Tregs in the tumor bed can be associated with an unfavorable prognosis. Drugs to block the function of Tregs activity increase t by T eff ectors and eff ect heart tee induce autoimmune disease. Questions in biology and prognosis of breast cancer in the presence of a St Of the immune system need to be examined.
The identifi cation of immunological and genetic features aff ected immune response in patients with minimal tumor burden is the perfect foundation for the development of clinical trials in the adjuvant setting. Research associated tumor antigens identified a large sheet has S collection of peptide epitopes that have been and will be used for the vaccination of patients with cancer. Several potential advantages of the use of vaccines based peptide Producing simple and relatively co S tze ZSTK474 Synthetic peptides, the administration of peptides in a clinical context, the M Possibility of treating only those patients whose tumors overexpress facilitate the target antigens and the availability of in vitro or ex vivo tests to evaluate patient immune response to the vaccine epitopes. The goal of future studies will be to the immunoreactivity t Many antigens in a large series of breast cancer specimens en assess ed classification by molecular subtypes.
On the identification of m Aligned objectives subpopulations of patients with breast cancer cation k Can the identifi cation of patients who are potential candidates for therapeutic vaccine adjuvants. It is our current considerations that patients with minimal residual disease after pr Operative chemotherapy the ideal setting to test the effi ciency of vaccination. To date, vaccines against breast cancer have primarily used in terminal illness. TAA antigens off a new opportunity to f the development of vaccines and therapeutic Rdern again. epithelial mesenchymal transition is an important process embroidered Lant w several events during development. EMT during evolution and embroidered l morphogenetic events, such as the formation of the three primary Ren Keimbl Tter w During gastrulation been preserved. Even more interestingly, have the signal transduction pathways were remarkably preserved in many diff erent ways. EMT pathways are closely reactivated with the determination diff erentiation and programs, and in adult tissues following injury or exposure to toxic substances. EMT is designed to operate in the early stages of invasion, intravasation lead to cancer of the blood or lymphatic.